Portfolio News

Aircuity Upgrades Dashboard with New Analytics Features

Aircuity, creator of measurably better environments, announces a redesigned analytics dashboard with many new features making it even easier to intelligently manage your buildings’ portfolio. Many of the new features were designed to analyze and display indoor environmental quality (IEQ) data making Aircuity’s dashboard a critical part of a healthy building strategy. Read more >>
Read more...

sam® Dramatically Improves the Treatment of Soft Tissue, Arthritis and Joint Issues Without Requiring Surgery or Pain Medication

sam® provides effective and safe treatment of soft tissue, arthritis and joint issues without the need for surgery or pain medication. The wearable device does so by stimulating blood flow for several hours per day to a localized region, delivering a powerful flow of nutrients to the site of an injury. Read more >>
Read more...

DOE funds 8 biomanufacturing projects

Today, the U.S. Department of Energy announced the selection of eight projects totaling over $5 million to conduct research and development (R&D) needed to accelerate the US biomanufacturing sector. Part of the Agile BioFoundry (ABF) consortium, these projects will leverage National Laboratory capabilities to address challenges in biomanufacturing - Kalion, Inc, of Milton, MA, will use machine learning and artificial intelligence to lower growth media production costs, increase productivity, and increase the overall commercial feasibility of biomanufacturing, with glucaric acid...
Read more...

Myomo launches MyoCare

Myomo announced today that it launched its MyoCare program for providing support to first-year users of its MyoPro powered brace.MyoCare offers expanded support to current and future clients who receive their MyoPro directly from the Cambridge, Mass.-based company, at no additional cost. Read more >>
Read more...

Pittsburgh biotech company wins funding for Covid-19 drug

Pittsburgh biotech company CytoAgents has received $250,000 from the Richard King Mellon Foundation to help develop its drug candidate to treat cytokine storm, a deadly complication of Covid-19 and other upper respiratory illnesses. CytoAgents has been working on phase I and phase II clinical trials for GP1681, its existing drug candidate that even before Covid-19 had treated the immune response that causes inflammation and respiratory distress for people with severe influenza. It received a $1.6 million grant from the National...
Read more...